Figure 1.

Uracil concentration distribution. (A) Uracil concentration distribution compared between wild type and DPYD variant carriers (heterozygous, compound heterozygous, and homozygous are pooled together). (B) Uracil concentration of wild-type patients with grade ≥3 FP-TOX compared to wild-type patients without toxicity.

FP, (5-fluorouracil, capecitabine, tegafur(S-1));